Plain-English translation of NCT04925609 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a medication called in children and young adults with certain cancers that have a specific genetic change called ALK. The study has two parts: first, researchers will find the safest and most effective dose, then they will test how well the medication works in a larger group of patients with specific cancer types.
Some children and young adults have cancers that have an ALK genetic change, and their disease may not respond well to standard treatments or may come back after treatment. This medication may offer a new option for these patients.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth as tablets, starting at a carefully determined dose. During the first part of the study, the dose may be adjusted as researchers find the best level. You will have regular visits to check how you are responding, including blood tests, scans, and physical exams. Your doctor will monitor you closely for any side effects and how well the medication is working.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
France
Netherlands